LeonaBio, Inc.: 5%+ holders

As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of LeonaBio, Inc. The largest reported stake is Sermonix Pharmaceuticals, Inc.'s, at 25.1%. 17 filings are on record since October 10, 2025 (Schedule 13D/A, October 28, 2026).

Oliveira Steven Michael also filed stake reports on 1 other company ↓

Sell to companies like LeonaBio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-11-04 · Reporting person: Great Point Partners, LLC · Sole voting: 0 · Shared voting: 474,345 · Sole dispositive: 0 · Shared dispositive: 474,345 · SCHEDULE 13G, 2026-11-04
• Filing 2026-10-28 · Reporting person: Sermonix Pharmaceuticals, Inc. · Sole voting: 0 · Shared voting: 3,149,470 · Sole dispositive: 0 · Shared dispositive: 3,149,470 · SCHEDULE 13D/A, 2026-10-28
• Event date 2026-10-26 · Holder: Perceptive Advisors LLC · Percent: 19.99% · Shares: 1,889,403 · SCHEDULE 13D/A
• Filed 2026-08-31 · Holder: Sermonix Pharmaceuticals, Inc. · Percent: 36.9% · SCHEDULE 13D
• Filed 2026-08-25 · Holder: Perceptive Advisors LLC · Percent: 19.99% · SCHEDULE 13D/A

LeonaBio, Inc. has 17 Schedule 13D or 13G filings on record since 2025-10-10. 5 holders' latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind LeonaBio, Inc. and the warning signs.

See LeonaBio, Inc.'s free Snapshot Watch LeonaBio, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on LeonaBio, Inc. and the records around it.

LeonaBio, Inc. elsewhere on the record

• Who owns it

Companies that share a holder

• Oliveira Steven Michael also filed stake reports on 1 other company: Forte Biosciences, Inc. (Jan 2026)
• ACORN BIOVENTURES, L.P. also filed stake reports on 5 other companies: Karyopharm Therapeutics Inc. (Oct 2026), enGene Therapeutics Inc. (Jul 2026), OnKure Therapeutics, Inc. (Apr 2026)
• Baselake Partners, LP also filed stake reports on 7 other companies: KIORA PHARMACEUTICALS, INC. (Sep 2026), Passage Bio, Inc. (Jun 2026), Generation Bio Co. (Feb 2026)

Want the whole picture on LeonaBio, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on LeonaBio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on LeonaBio, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   17 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies LeonaBio, Inc. by CUSIP 04746L203 and gives its principal executive office as 18706 North Creek Parkway, Suite 104, Bothell, WA 98011 (SCHEDULE 13G, 2026-11-04).

What the percentages are based on

The percentages set forth herein are calculated based upon 9,421,663 shares of Common Stock outstanding as of August 12, 2026 as reported in the firm's 2nd Quarter 2026 Form 10Q filed on August 14, 2026.Anders Hove, SCHEDULE 13G/A, 2026-08-20

Source of funds (Item 3)

As contemplated in the original Schedule 13D filing, the prefunded warrant providing for the right to acquire 5,502,402 shares of Issuer's common stock was exercised, in part, on 10/26/2026 for the purchase and issuance of 3,149,470 shares of Issuer. The balance of the prefunded warrant was assigned to Perceptive Xontogeny Venture Fund 11, LP ("PXV II") as a distribution in kind pursuant to the previously disclosed distribution of securities to owners of Sermonix's common stock, and a new prefunded warrant for the remaining 2,352,932 common shares was issued to PXV II.Sermonix Pharmaceuticals, Inc., SCHEDULE 13D/A, 2026-10-28

Purpose of Transaction (Item 4)

Sermonix Pharmaceuticals, Inc.

The assignment of the remaining prefunded warrant rights to acquire 2,352,932 common shares of Issuer effects the previously disclosed distribution-in-kind to PXV II as part of the plan of distribution to the owners of Sermonix's common stock as described in the original Schedule 13D and Item 5.Item 4 of the SCHEDULE 13D/A filed 2026-10-28

Timeline

Swipe the table sideways to see every column.

Questions about who owns LeonaBio, Inc.

Who owns LeonaBio, Inc.?

On this page, 5 holders' latest ownership filings report 5% or more of LeonaBio, Inc.: Sermonix Pharmaceuticals, Inc. (25.1%, Schedule 13D/A, filed 2026-10-28), Perceptive Advisors LLC (19.99%, Schedule 13D/A, filed 2026-10-26), Anders Hove (12.1%, Schedule 13G/A, filed 2026-08-20), ADAR1 Capital Management, LLC (7.7%, Schedule 13G, filed 2026-05-15) and Great Point Partners, LLC (5.03%, Schedule 13G, filed 2026-11-04).

Who are the largest shareholders of LeonaBio, Inc.?

By the share each holder's latest filing reports, the largest holders of LeonaBio, Inc. on this page are Sermonix Pharmaceuticals, Inc. (25.1%), Perceptive Advisors LLC (19.99%) and Anders Hove (12.1%).

When did Sermonix Pharmaceuticals, Inc. buy into LeonaBio, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Sermonix Pharmaceuticals, Inc. on this page is the Schedule 13D, filed 2026-08-31, reporting 36.9%; its latest, Schedule 13D/A filed 2026-10-28, reports 25.1%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 17 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Tools for this story

Each opens in a new tab, filled in for LeonaBio, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when LeonaBio, Inc. is mentioned again
• Find former LeonaBio, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes